Peterlabs Holdings BhdXKLS:0171 47 Return-on-Tangible-Equity is -8.02% as of Jun. 2025. GuruFocus rates XKLS:0171 with a GF Score™ of 47/100. Among 897 Drug Manufacturers companies, Peterlabs Holdings Bhd ranks worse than 68.78% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Peterlabs Holdings Bhd's annualized net income for the quarter that ended in Jun. 2025 was RM-5.5 Mil. Peterlabs Holdings Bhd's average shareholder tangible equity for the quarter that ended in Jun. 2025 was RM68.6 Mil. Therefore, Peterlabs Holdings Bhd's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2025 was -8.02%.
The historical rank and industry rank for Peterlabs Holdings Bhd's Return-on-Tangible-Equity or its related term are showing as below:
XKLS:0171's Return-on-Tangible-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.9 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
Peterlabs Holdings Bhd (XKLS:0171) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Peterlabs Holdings Bhd Return-on-Tangible-Equity Related Terms
Peterlabs Holdings Bhd Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Peterlabs Holdings Bhd's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Peterlabs Holdings Bhd Return-on-Tangible-Equity Chart
XKLS:0171 vs ZTS, UTHR, VTRS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Peterlabs Holdings Bhd's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Peterlabs Holdings Bhd Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Peterlabs Holdings Bhd's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Peterlabs Holdings Bhd's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -8.02% mean?
Peterlabs Holdings Bhd (XKLS:0171) has a Return-on-Tangible-Equity of -8.02% as of Jun. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Peterlabs Holdings Bhd and its competitors. According to the industry distribution chart, Peterlabs Holdings Bhd ranks #617 out of 897 companies in the Drug Manufacturers industry, placing it in the top 68.8%.
Is Peterlabs Holdings Bhd's Return-on-Tangible-Equity too high?
Peterlabs Holdings Bhd's current Return-on-Tangible-Equity is -8.02%. Based on the distribution chart, Peterlabs Holdings Bhd ranks #617 out of 897 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Peterlabs Holdings Bhd has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Peterlabs Holdings Bhd's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Peterlabs Holdings Bhd ranks #617 out of 897 companies for Return-on-Tangible-Equity. This places Peterlabs Holdings Bhd in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 897 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Peterlabs Holdings Bhd and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Peterlabs Holdings Bhd's current Return-on-Tangible-Equity is -8.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Peterlabs Holdings Bhd stock overvalued right now?
Peterlabs Holdings Bhd (XKLS:0171) has a current Return-on-Tangible-Equity of -8.02%. The current Return-on-Tangible-Equity is -8.02%. Peterlabs Holdings Bhd's overall GF Score™ is 47/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Peterlabs Holdings Bhd (XKLS:0171), the current Return-on-Tangible-Equity is -8.02% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Peterlabs Holdings Bhd is engaged in the manufacturing, distribution, export, and trading of animal health and nutrition products. The Group offers biosecurity and disinfectants, compound feed supplements, feed additives, nutritional premixes, pharmaceuticals, and water-soluble supplements, as well as farm management, technical advisory services, raw material analysis, and feed formulation. Its segments are Manufacturing, which covers the manufacturing and distribution of animal health and nutrition products; Trading, which involves the trading and distribution of animal health and nutrition products and consumer goods, and contributes the majority of its revenue; and Others, which provides investment holding services. The company operates in Malaysia and internationally.
47GF Score
Get the complete analysis for XKLS:0171
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0171 has been successfully added to your 
